| Literature DB >> 23662040 |
Fukuko Hayamizu1, Yoshio Yamazaki, Takako Nakagami, Kenji Mizuki.
Abstract
PURPOSE: Our goal was to evaluate the influence of optic disc size on the progression of visual field damage in patients with normal-tension glaucoma (NTG). SUBJECTS AND METHODS: Eighty-two eyes of 82 NTG patients who had been receiving topical antiglaucoma medications and followed-up for more than 4 years were enrolled in this study. The patients were allocated to two groups, according to the mean size of their optic discs. The data were analyzed using regression analysis, based on the Cox proportional hazard model.Entities:
Keywords: Cox proportional hazards model; Kaplan–Meier life-table analysis; disc hemorrhage; disc size; intraocular pressure
Year: 2013 PMID: 23662040 PMCID: PMC3647604 DOI: 10.2147/OPTH.S42468
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Clinical data for all enrolled subjects (n = 82)
| Age (years) | 58.0 ± 9.3 | (33–74) |
| Sex (number, male/female) | 34/48 | |
| Duration of follow-up (months) | 103 ± 29 | (51–173) |
| MD (decibels) | −8.7 ± 5.2 | (−19.9 to 0.5) |
| CPSD (decibels) | 9.9 ± 4.6 | (2.1–18.6) |
| Refraction (diopters) | −1.1 ± 2.4 | (−6.0 to 3.0) |
| CCT (mm) | 0.50 ± 0.04 | (0.42–0.66) |
| Axial length (mm) | 23.8 ± 1.3 | (21.1–26.6) |
| Disc area (mm2) | 2.41 ± 0.57 | (1.30–3.82) |
| DH (number, positive/negative) | 19/63 | |
| Number of antiglaucoma agents | 1.7 ± 0.7 | (1–3) |
| IOP of diurnal variation (mmHg) | ||
| Mean | 13.7 ± 1.9 | (8.8–17.9) |
| Maximum | 16.4 ± 2.2 | (12.0–21.0) |
| Minimum | 11.0 ± 2.0 | (6.0–16.0) |
| IOP during follow-up (mmHg) | ||
| Mean | 13.0 ± 1.6 | (9.4–16.4) |
| Maximum | 16.3 ± 2.2 | (12.0–21.0) |
| Minimum | 9.9 ± 1.6 | (6.0–14.0) |
| IOP reduction ratio (%) | 4.2 ± 9.8 | (−20.6 to 29.0) |
| Prevalence of receiving topical medications during follow-up | ||
| PG | 11 | |
| AI | 29 | |
| CAI | 1 | |
| PG + AI | 27 | |
| PG + CAI | 3 | |
| AI + CAI | 4 | |
| PG + AI + CAI | 7 | |
Notes: Values are presented as mean ± standard deviation (range). IOP reduction ratio = (mean IOP of diurnal variation − mean IOP during follow-up)/mean IOP of diurnal variation × 100.
Abbreviations: n, number; MD, mean deviation; CPSD, corrected pattern standard deviation; CCT, central corneal thickness; DH, occurrence of disc hemorrhage; IOP, intraocular pressure; PG, prostaglandins; AI, adrenergic inhibitors (α, β); CAI, carbonic anhydrase inhibitors.
Figure 1Distribution of optic disc area for all subjects.
Notes: Mean value was 2.41 mm2 and standard deviation was 0.57 mm2 (range: 1.30 mm2 to 3.82 mm2).
Clinical data for eyes with large versus small discs
| Variable | Eyes with large disc area (n = 38) | Eyes with small disc area (n = 44) | |
|---|---|---|---|
| Age (years) | 57.17 ± 9.6 | 58.7 ± 9.1 | ns |
| Sex (number, male/female) | 16/22 | 18/26 | ns |
| Duration of follow-up (months) | 102 ± 30 | 103 ± 28 | ns |
| MD (decibels) | −8.8 ± 4.8 | −8.7 ± 5.5 | ns |
| CPSD (decibels) | 9.2 ± 4.8 | 10.4 ± 4.4 | ns |
| Refraction (diopters) | −1.5 ± 2.5 | −0.8 ± 2.3 | ns |
| CCT (mm) | 0.50 ± 0.04 | 0.49 ± 0.03 | ns |
| Axial length (mm) | 24.1 ± 1.3 | 23.6 ± 1.3 | ns |
| Disc area (mm2) | 2.91 ± 0.37 | 1.98 ± 0.26 | 0.000 |
| DH (number, positive/negative) | 10/28 | 9/35 | ns |
| Number of antiglaucoma agents | 1.7 ± 0.8 | 1.7 ± 0.6 | ns |
| IOP of diurnal variation (mmHg) | |||
| Mean | 13.5 ± 1.9 | 13.9 ± 1.8 | ns |
| Maximum | 16.1 ± 2.5 | 16.7 ± 2.0 | ns |
| Minimum | 10.8 ± 2.0 | 11.2 ± 2.0 | ns |
| IOP during follow-up (mmHg) | |||
| Mean | 12.9 ± 1.7 | 13.2 ± 1.6 | ns |
| Maximum | 16.1 ± 2.2 | 16.4 ± 2.1 | ns |
| Minimum | 9.7 ± 1.8 | 10.1 ± 1.5 | ns |
| IOP reduction ratio (%) | 4.1 ± 10.0 | 4.6 ± 9.8 | ns |
| Progression of visual field damage (positive/negative) | 26/12 | 17/27 | 0.009 |
| Prevalence of receiving topical medications during follow-up | 0.301 | ||
| PG | 5 | 6 | |
| AI | 16 | 13 | |
| CAI | 1 | 0 | |
| PG + AI | 8 | 19 | |
| PG + CAI | 1 | 2 | |
| AI + CAI | 3 | 1 | |
| PG + AI + CAI | 4 | 3 | |
Notes: Values are presented as mean ± standard deviation;
unpaired Student’s t-test;
Fisher’s exact test IOP reduction ratio = (Mean IOP of diurnal variation – Mean IOP during follow-up)/Mean IOP of diurnal variation × 100.
Abbreviations: n, number; ns, not significant; MD, mean deviation; CPSD, corrected pattern standard deviation; CCT, central corneal thickness; DH, occurrence of disc hemorrhage; IOP, intraocular pressure; PG, prostaglandins; AI, adrenergic inhibitors (α, β); CAI, carbonic anhydrase inhibitors.
Figure 2The probability of visual field stability, according to optic disc size.
Notes: •, eyes with small discs; ■, eyes with large discs. There is a statistically significant difference in the probability of visual field damage between eyes with small discs and those with large discs at 102 months. P = 0.007 (log rank test).
Clinical data for eyes with and without progressive visual field damage
| Variable | Eyes with progressive visual field damage (n = 43) | Eyes without progressive visual field damage (n = 39) | |
|---|---|---|---|
| Age (years) | 57.2 ± 9.9 | 58.8 ± 8.7 | ns |
| Sex (number, male/female) | 16/27 | 18/21 | ns |
| Duration of follow-up (months) | 105 ± 30 | 100 ± 28 | ns |
| MD (decibels) | −8.7 ± 4.5 | −8.8 ± 5.8 | ns |
| CPSD (decibels) | 10.0 ± 4.5 | 9.7 ± 4.8 | ns |
| Refraction (diopters) | −1.4 ± 2.5 | −0.8 ± 2.2 | ns |
| CCT (mm) | 0.50 ± 0.03 | 0.49 ± 0.05 | ns |
| Axial length (mm) | 23.9 ± 1.4 | 23.7 ± 1.2 | ns |
| Disc area (mm2) | 2.57 ± 0.57 | 2.25 ± 0.52 | 0.009 |
| DH (number, positive/negative) | 15/28 | 4/35 | 0.010 |
| Number of antiglaucoma agents | 1.6 ± 0.7 | 1.7 ± 0.7 | ns |
| IOP of diurnal variation (mmHg) | |||
| Mean | 13.6 ± 1.6 | 13.8 ± 2.1 | ns |
| Maximum | 16.3 ± 2.0 | 16.6 ± 2.4 | ns |
| Minimum | 10.8 ± 1.7 | 11.2 ± 2.3 | ns |
| IOP during follow-up (mmHg) | |||
| Mean | 13.1 ± 1.6 | 12.9 ± 1.7 | ns |
| Maximum | 16.2 ± 2.1 | 16.5 ± 2.3 | ns |
| Minimum | 10.0 ± 1.8 | 9.8 ± 1.6 | ns |
| IOP reduction ratio (%) | 3.1 ± 10.2 | 5.1 ± 9.3 | ns |
| Prevalence of receiving topical medications during follow-up | 0.700 | ||
| PG | 5 | 6 | |
| AI | 17 | 12 | |
| CAI | 1 | 0 | |
| PG + AI | 11 | 16 | |
| PG + CAI | 2 | 1 | |
| AI + CAI | 3 | 1 | |
| PG + AI + CAI | 4 | 3 | |
Notes: Values are presented as mean ± standard deviation;
unpaired Student’s t-test;
Fisher’s exact test. IOP reduction ratio = (Mean IOP of diurnal variation − Mean IOP during follow-up)/Mean IOP of diurnal variation × 100.
Abbreviations: n, number; ns, not significant; MD, mean deviation; CPSD, corrected pattern standard deviation; CCT, central corneal thickness; DH, occurrence of disc hemorrhage; IOP, intraocular pressure; PG, prostaglandins; AI, adrenergic inhibitors (α, β); CAI, carbonic anhydrase inhibitors.
Factors identified as associated with progression of visual field damage in patients with NTG (n = 82)
| Factors | Hazard ratio | 95% confidence interval | |
|---|---|---|---|
| Disc area by 1 mm2 increase | 1.812 | 1.110–2.961 | 0.018 |
| Occurrence of disc hemorrhage | |||
| Absence | 1 | ||
| Presence | 2.116 | 1.082–4.136 | 0.028 |
| IOP reduction ratio by 1% increase | 0.957 | 0.925–0.991 | 0.014 |
Note: IOP reduction ratio = (Mean IOP of diurnal variation − Mean IOP during follow-up)/Mean IOP of diurnal variation × 100.
Abbreviations: NTG, normal-tension glaucoma; n, number; IOP, intraocular pressure.